130 mCi NYMO32 + 200 mCi NYMO32 + 30 mCi NYMO32 + 50 mCi NYMO32 + 80 mCi NYMO32 for neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trial registered. A trial in people is registered. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 14 Feb 2025: Trial registered, NCT06827080

The trials

NCT06827080: Study on the Safety, Tolerability, and Preliminary Efficacy of 161Tb-NYM032 in Patients with Metastatic Castration-Resistant Prostate Cancer

State
Not started
Phase
Phase 1 and Phase 2
People
15 planned
Started
11 Feb 2025
Primary completion
1 Dec 2026
Arms
161Tb-NY032
Results
None posted
  1. 14 Feb 2025: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Trial registered

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.